Insider Selling: BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Sells $149,991.68 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Brian C. Stephenson sold 4,148 shares of the stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $36.16, for a total value of $149,991.68. Following the completion of the transaction, the chief financial officer now owns 102,464 shares of the company’s stock, valued at approximately $3,705,098.24. This trade represents a 3.89 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

BridgeBio Pharma Stock Up 0.1 %

NASDAQ BBIO opened at $36.85 on Friday. The company has a 50-day moving average price of $31.90 and a 200-day moving average price of $27.93. BridgeBio Pharma, Inc. has a 52 week low of $21.62 and a 52 week high of $39.47. The firm has a market capitalization of $6.96 billion, a P/E ratio of -15.29 and a beta of 1.07.

BridgeBio Pharma (NASDAQ:BBIO) last announced its earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The company had revenue of $5.88 million for the quarter, compared to the consensus estimate of $4.04 million. As a group, equities research analysts anticipate that BridgeBio Pharma, Inc. will post -2.56 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on BBIO shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $95.00 price target on shares of BridgeBio Pharma in a research note on Friday. HC Wainwright reiterated a “buy” rating and set a $49.00 target price on shares of BridgeBio Pharma in a report on Thursday, February 13th. Citigroup upped their price target on BridgeBio Pharma from $45.00 to $49.00 and gave the stock a “buy” rating in a research note on Friday. Scotiabank lifted their price objective on BridgeBio Pharma from $49.00 to $52.00 and gave the company a “sector outperform” rating in a research note on Friday. Finally, Evercore ISI increased their target price on BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a research note on Monday, December 23rd. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.67.

Institutional Investors Weigh In On BridgeBio Pharma

Several hedge funds and other institutional investors have recently modified their holdings of BBIO. Steward Partners Investment Advisory LLC grew its holdings in BridgeBio Pharma by 85.8% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company’s stock valued at $28,000 after purchasing an additional 472 shares during the period. Itau Unibanco Holding S.A. purchased a new position in shares of BridgeBio Pharma during the 4th quarter valued at about $41,000. Sterling Capital Management LLC grew its stake in shares of BridgeBio Pharma by 554.6% during the 4th quarter. Sterling Capital Management LLC now owns 1,787 shares of the company’s stock valued at $49,000 after acquiring an additional 1,514 shares during the period. Values First Advisors Inc. purchased a new stake in BridgeBio Pharma in the 3rd quarter worth approximately $57,000. Finally, CWM LLC raised its stake in BridgeBio Pharma by 132.9% during the 3rd quarter. CWM LLC now owns 3,442 shares of the company’s stock worth $88,000 after acquiring an additional 1,964 shares during the period. 99.85% of the stock is currently owned by hedge funds and other institutional investors.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.